SS Innovations Reiterates Q1 Guidance Of ~$6.4M; Says SSi Mantra Robotic Surgical System Orders Totaled 9 In The First Month Of Q2, April 2025, Up 200% From 3 Orders In April 2024
Benzinga Newsdesk 1 year ago
NewsGuidance
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, "Following our recent uplisting to Nasdaq, we remain very pleased with the growth trajectory of our business as we
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, "Following our recent uplisting to Nasdaq, we remain very pleased with the growth trajectory of our business as we conclude the first quarter of 2025 and enter the second quarter. We believe that we are well-positioned to maintain this momentum and achieve new and impactful milestones throughout 2025."
The Company reiterated:
- 14 SSi Mantra surgical robotic systems were installed during the first quarter of 2025, bringing the cumulative installed base to 78 as of March 31, 2025.
- Revenue for the first quarter of 2025 is expected to be approximately $6.4 million with a gross margin of approximately 45%, based on preliminary unaudited results which are subject to change.
The Company also provided the following updates:
- As of April 30, 2025, 80 SSi Mantra robotic surgical systems have been installed in 75 hospitals and more than 3800 surgeries have utilized the SSi Mantra, including over 200 robotic cardiac surgeries.
- SSi Mantra robotic surgical system orders totaled 9 in the first month of the second quarter, April 2025, up 200% from 3 orders in April 2024.
The Company anticipates reporting first quarter 2025 financial results on or about May 15, 2025.